Rho激酶抑制剂Ripasudil治疗青光眼的Meta分析

Meta-analysis of Rho kinase inhibitor Ripasudil in the treatment of glaucoma

目的:采用Meta分析系统性评价Rho激酶抑制剂Ripasudil对青光眼的治疗效果。方法:通过检索三个数据库(Pubmed、Web of Knowledge和CNKI),检索Ripasudil治疗青光眼的临床试验,检索发表日期为2015-01/2019-04。采用眼内压(IOP)作为结局指标,WMD和95%CI评价结果,并根据青光眼类型分为原发性开角型青光眼、继发性青光眼、多种类型进行亚组分析。结果:共纳入9篇文献,全部为英文文献,与对照组相比,试验组IOP显著降低(WMD=-2.96,95%CI-3.48^-2.45,P<0.001)。去除导致高度异质性的文献后,亚组分析组间差异明显。结论:Ripasudil对降低眼压有显著作用,可用于治疗青光眼,但对不同类型的青光眼治疗效果仍有差异。Ripasudil有结膜充血等副作用,但停药以后副作用消失。

AIM:To evaluate the efficacy and safety of ripasudil in the treatment of glaucoma in recent years by Meta-analysis.METHODS:According to the Cochrane systematic review method,we searched three databases(Pubmed,Web of Knowledge and CNKI).The change of intraocular pressure was used to assess the effect of ripasudil,WMD with 95%confidence intervals(CI)were used to report the outcome.Subgroup analysis was performed according to different types of glaucoma.RESULTS:A total of 9 trials all in English,totally 3446 patients,Meta-analysis showed that compared with before-treated groups,after-treated groups have significant lower IOP(Test of WMD=-2.96 95%CI:-3.48 to-2.45,P<0.001),which indicates that ripasudil has great efficacy of curing glaucoma.